APIs to the rescue?

Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation strategies – including amorphous solid dispersions, nanosizing and lipid carriers – alongside advanced data analytics and AI-driven approaches to accelerate discovery, enhance solubility and reduce development timelines for traditionally hard-to-formulate drugs.